Amphastar-Momenta rivalry regarding generic heparin intensifies
Sens. Max Baucus, D-Mont., and Chuck Grassley, R-Iowa, launched an investigation into Amphastar Pharmaceuticals' hiring of security company Kroll, as the drugmaker competes with Momenta Pharmaceuticals to gain FDA approval for a generic version of low-molecular-weight heparin. Amphastar's general counsel said the company asked Kroll to look into a possible conflict of interest between Janet Woodcock, head of the FDA's drug unit, and a co-founder of Momenta.
Wall Street Journal, The | 11/02
This story published in FDLI SmartBrief on 11/02/2009
More from SmartBrief:
HHS investigates FDA official over conflict-of-interest claim
Wednesday, August 12, 2009
Get stories like these delivered daily for FREE:
|
FDLI SmartBrief
Designed specifically for professionals involved in the food and drug industry, FDLI SmartBrief is a FREE daily e-mail newsletter. It provides the latest need-to-know news and industry information that maximizes your time, giving you an edge over your competition. Learn more |
|